Opdivo nivolumab: Interim Phase II data

Interim data from 74 evaluable previously treated mCRC patients with MSI-H in the open-label, international Phase II Checkmate -142 trial showed that 3 mg/kg IV Opdivo every 2 weeks

Read the full 298 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE